Guggenheim initiated coverage of Keros Therapeutics with a Buy rating and $96 price target. Keros is a clinical-stage biotechnology company that focuses on transforming the growth factor-beta superfamily signaling pathway and its role in various diseases, the analyst tells investors in a research note. The firm’s bullish view of Keros is driven primarily by its expectations for cibotercept in pulmonary arterial hypertension. It believes there is a significant commercial opportunity in PAH for cibotercept if it is able to demonstrate a clinical profile showing efficacy similar to or better than that seen with Winrevair, while avoiding the bleeding risks and other hematological side effects associated with that drug.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $76 from $81 at BofA
- Keros Therapeutics closes screening for Phase 2 trial of cibotercept
- Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
- Keros Therapeutics CEO to Speak at Major Healthcare Conferences
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences